XML 33 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Data
 12 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Segment Data Segment Data
The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services.
Medical
Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. Medical consists of the following organizational units: Medication Delivery Solutions; Medication Management Solutions; Pharmaceutical Systems; Advanced Patient Monitoring.
Life Sciences
Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; physicians’ office practices; academic and government institutions; and pharmaceutical and biotechnology companies. Life Sciences consists of the following organizational units: Integrated Diagnostic Solutions and Biosciences.
Interventional
Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by Interventional are hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via the segment's Homecare business. Interventional consists of the following organizational units: Surgery; Peripheral Intervention; Urology and Critical Care.
Additional Segment Information
Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented.
Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income, which represents revenues reduced by product costs and operating expenses. The Company’s chief operating decision maker does not receive any asset information by business segment and, as such, the Company does not report asset information by business segment.
The tables below reflect the Company’s revenues and operating income from continuing operations. Revenues and operating income from the former Diabetes Care business prior to its spin-off on April 1, 2022 are included in (Loss) Income from Discontinued Operations, Net of Tax. See Note 2 for further information.
Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.
(Millions of dollars)202420232022
United StatesInternationalTotalUnited StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$2,661 $1,768 $4,429 $2,519 $1,774 $4,293 $2,483 $1,825 $4,308 
Medication Management Solutions2,627 670 3,297 2,303 677 2,980 1,935 598 2,533 
Pharmaceutical Systems629 1,644 2,273 666 1,563 2,229 533 1,468 2,001 
Advanced Patient Monitoring47 27 74 — — — — — — 
Total segment revenues$5,964 $4,110 $10,074 $5,488 $4,014 $9,502 $4,950 $3,891 $8,841 
Life Sciences
Integrated Diagnostic Solutions$1,733 $1,946 $3,679 $1,774 $1,850 $3,624 $2,190 $1,995 $4,185 
Biosciences577 935 1,512 603 906 1,509 542 838 1,379 
Total segment revenues$2,310 $2,881 $5,191 $2,377 $2,756 $5,133 $2,732 $2,833 $5,564 
Interventional
Surgery $1,130 $363 $1,492 $1,159 $338 $1,497 $1,094 $306 $1,400 
Peripheral Intervention1,029 904 1,933 1,016 849 1,865 960 799 1,759 
Urology and Critical Care1,236 319 1,554 1,073 301 1,374 986 319 1,305 
Total segment revenues$3,394 $1,586 $4,980 $3,247 $1,489 $4,736 $3,040 $1,424 $4,464 
Other (a)$(6)$(62)$(67)$— $— $— $— $— $— 
Total Company revenues from continuing operations$11,663 $8,515 $20,178 $11,113 $8,258 $19,372 $10,722 $8,148 $18,870 
(a)    Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 6.
The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization.
(Millions of dollars)202420232022
Income from Continuing Operations Before Income Taxes
Medical (a) (b) $2,742 $1,967 $2,215 
Life Sciences1,595 1,585 1,710 
Interventional 1,420 1,217 1,081 
Total Segment Operating Income
5,758 4,769 5,006 
Integration, restructuring and transaction expense(458)(313)(173)
Net interest expense(364)(403)(382)
Other unallocated items (c)(2,931)(2,391)(2,668)
Total Income from Continuing Operations Before Income Taxes$2,005 $1,662 $1,783 
Capital Expenditures
Medical$438 $563 $602 
Life Sciences114 139 213 
Interventional127 138 130 
Corporate and All Other46 35 28 
Total Capital Expenditures$725 $874 $973 
Depreciation and Amortization
Medical$1,216 $1,199 $1,144 
Life Sciences272 277 283 
Interventional786 799 789 
Corporate and All Other13 13 13 
Total Depreciation and Amortization$2,286 $2,288 $2,229 
(a)The amounts in 2024, 2023 and 2022 include charges of $38 million, $653 million and $72 million, respectively, recorded to Cost of products sold, to record or adjust future costs estimated for product remediation efforts.
(b)The amount in 2022 includes a charge of $54 million, recorded to Cost of products sold, to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit.
(c)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount in 2024 includes a charge of $175 million to accrue an estimated liability for the SEC investigation, which is further discussed in Note 6. The amount in 2023 includes a pre-tax gain recognized on the Company's sale of its Surgical Instrumentation platform of approximately $268 million, which is further discussed in Note 2.
Geographic Information
The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); and Other, which is comprised of Latin America (which includes Mexico, Central America, the Caribbean and South America) and Canada.
Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.
The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area:
(Millions of dollars)202420232022
Revenues
United States$11,663 $11,113 $10,722 
EMEA4,402 4,244 4,043 
Greater Asia2,906 2,913 3,047 
Other1,207 1,102 1,058 
$20,178 $19,372 $18,870 
Long-Lived Assets
United States$35,526 $35,732 $36,617 
EMEA6,706 5,317 5,126 
Greater Asia1,580 1,521 1,528 
Other2,548 1,116 1,079 
Corporate459 418 442 
$46,818 $44,104 $44,792